We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dyax Reports Positive Findings From HAE Study

Dyax Reports Positive Findings From HAE Study

April 13, 2007

Dyax has announced positive topline results from its Phase III, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88, for hereditary angioedema (HAE).

DX-88 (ecallantide), an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of HAE, a rare genetic disease characterized by episodes of acute swelling and inflammation. Statistically significant results were achieved for both the primary and secondary endpoints in the EDEMA3 trial.

EDEMA3, a 72-patient, placebo-controlled, multicenter, Phase III trial, was conducted at 34 sites in the U.S., Europe, Canada and Israel. The primary objective of EDEMA3 was to determine the efficacy and safety of the fixed 30-mg subcutaneous (SC) dose of DX-88 for patients suffering from moderate to severe acute HAE attacks. The trial had two phases: a double-blind, placebo-controlled phase and a repeat-dosing phase. In the first phase, HAE patients received either a single 30-mg SC dose of DX-88 or placebo. After patients received one treatment in the placebo-controlled portion of the study, they were eligible for the second, open-label phase of the study, where they receive repeat dosing with SC DX-88 for any subsequent attacks.

The primary endpoint, symptom improvement at four hours measured by a treatment outcome score developed for HAE attacks, as well as the two secondary endpoints, demonstrated statistical significance. Time to significant improvement in overall response had a median time of 149 minutes for the DX-88 group versus greater than four hours for the placebo group. The overall safety results showed that DX-88 continues to be well tolerated. There were no drug-related serious adverse events.

"Based on the topline results of this study, the extensive clinical data collected to date and the pending completion of the EDEMA4 confirmatory trial already under way, we believe we will be well positioned to apply for regulatory approval to bring to market this much needed therapy for the HAE patient community," Henry Blair, chairman and CEO of Dyax, said.

KEYWORDS Drug Pipeline Alert

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing